Removal of one, two and four amino-acid residues from the C-terminus of f,-endorphin ('lipotropin C-Fragment', lipotropin residues 61-91) led to the formation of peptides with progressively decreased analgesic potency; there was no change in the persistence of the analgesic effects. The four C-terminal residues are thus important for the activity of f1-endorphin, but not for the duration of action. Removal of eight amino-acid residues from the N-terminus provided a peptide that had no specific affinity for brain opiate receptors in vitro and was devoid of analgesic properties. The N-terminal sequence of fi-endorphin is therefore necessary for the production of analgesia, whereas the C-terminal residues confer potency. The Na-acetyl form of f-endorphin had no specific affinity for brain opiate receptors in vitro and possessed no significant analgesic properties. Since lipotropin C'-Fragment (lipotropin residues 61-87) and the Na-acetyl derivative of ,6-endorphin occur naturally in brain and pituitary and are only weakly active or inactive as opiates, it is suggested that proteolysis at the C-terminus and acetylation at the N-terminus of fJ-endorphin may constitute physiological mechanisms for inactivation of this potent analgesic peptide.
The pentapeptide, [methionine5lenkephalin, was shown to exist in porcine brain and act as a ligand of the opiate receptor by Hughes et al. (1975) . It was found to behave like morphine in peripheral opiate assays, but it had only a weak and transient analgesic action when administered intraventricularly in the rat (Beluzzi et al., 1976) , cat (Feldberg & Smyth, 1976) or mouse (Buscher et al., 1976) . With the elucidation of the primary structure, it became clear that [methionine5lenkephalin corresponds to five residues at the N-terminus off,-endorphin, a 31-residue peptide first isolated from porcine pituitary glands (Bradbury et al., 1975). f.-Endorphin, originally called the C-Fragment of lipotropin (lipotropin residues 61-91), shares with enkephalin certain morphine-like actions in opiate assays in vitro, but it appears to have a higher affinity for brain opiate receptors and possesses strong analgesic properties (Feldberg & Smyth, 1976 Bradbury et al., 1976; Van Ree et al., 1976; Loh et al., 1976) . The relatively high analgesic potency and long duration of action of fJ-endorphin may be attributed to the peptide chain that extends from the N-terminal region, but it is notable that lipotropin C'-Fragment (lipotropin residues 61-87), which lacks four residues from the C-terminus of fi-endorphin, has little analgesic potency (Feldberg & Smyth, 1977; Geisow et al., 1977 was observed when the tests were separated by a week.
The tail-flick assay employed in these studies is widely used for the determination of analgesia. It is important to note that whereas the inhibitory motor effects commonly induced by opiate substances might interfere with tail-flick response, particularly at high doses, other drugs that cause muscular rigidity (for example, neuroleptics) do not increase tail-flick latency.
Determination ofaffinityfor brain opiate receptors
Binding studies were performed as described previously (Fig. 3) .
Although extensive behavioural observations were not carried out, morphine-like effects were noted at higher doses of all the peptides. 'Wet-dog' shakes were observed within 5 min of injection, the effects diminishing as analgesia developed. Later, rigidity and Straub tail (stiff, extended tail) developed and 90min or more after peptide injection mild hyperactivity and stereotyped chewing movements were exhibited and continued after the animals were returned to their home cages.
The analgesic and cataleptic effects produced by fl-endorphin (1 nmol) were reversed by 2. ; also included is a control group of saline-injected animals. At most doses the analgesic effects of the larger peptides took at least 30min to develop maximally, whereas [D-Ala2lenkephalinamide produced its greatest effect within 10min. Fig. 6 shows the time course of analgesia of the different peptides at doses selected to produce the same maximum effect. The duration of action of the C'-Fragment (lipotropin residues 61-87), the 30-residue peptide lipotropin residues 61-90 and 16-endorphin (lipotropin residues 61-91) were similar, tail-flick latencies remaining increased for at least 90min. In contrast the analgesic action of [D-Ala2lenkephalin-amide had ceased by 30 min. The analgesic effects of morphine followed a similar time course to those of the larger peptides, with peak effects taking 30min to develop.
Properties of Na-acetyl-fI-endorphin At concentrations of 50UM, Na-acetyl-flendorphin gave no significant displacement of [3Hlnaloxone from brain synaptosomal membranes in vitro, whereas the IC50 value of f6-endorphin was found to be 4.8nm. Thus the acetylated derivative did not appear to bind specifically to the opiate receptor. The Nct-acetyl derivative of fJ-endorphin was found to have no significant analgesic activity when tested in the rat at doses 100 and 200 times greater than a threshold dose off,-endorphin (Fig.  2 ).
Discussion
It is well known that the rank order of potency of certain opiates differs in different assays and it is generally accepted that this reflects the presence of different types of opiate receptor. In the guineapig ileum assay, for example, each of the naturally occurring peptides shown in Fig. (i-endorphin, lipotropin C'-Fragment and [methionine5lenke-phalin) exhibits a similar potency ; but with respect to the production of analgesia, ,B-endorphin is outstandingly active.
It has been suggested that the high potency of fJ-endorphin as an analgesic agent is conferred on the peptide by its 'address' sequence of amino acids, the address region being formed from the C-terminal residues, which potentiate the specific binding affinity between the N-terminal 'message' region and the complementary 16-endorphin receptor (Smyth, 1980 (Austen & Smyth, 1977) . . The role ofthe N-terminus offi-endorphin
The N-terminal region of fl-endorphin contains the pentapeptide sequence of enkephalin, which itself has morphine-like properties. It seems likely, therefore, that the N-terminus of f,-endorphin provides a binding site for the analgesic receptors, whereas the remaining section of the peptide chain either enhances the affinity of the N-terminal region for the receptor or constitutes a second binding site. In addition the length of the peptide chain appears to protect the molecule from enzymic degradation (Austen et al., 1979) . The absence of activity in the truncated f,-endorphin (lipotropin residues 69-91) and in the N-aacetyl derivative of fl-endorphin indicates that if there is a C-terminal receptor, then activation of that receptor does not lead to the production of analgesia, The evidence supports a view that the C-terminal tetrapeptide, though remote from the N-terminus in the' linear sequence, potentiates the activity of fJ-endorphin by enhancing the affinity of its N-terminal region for the analgesic receptors. The lack of potency but long duration of action of lipotropin residues 61-87 suggests that protection of the enkephalin sequence from enzymic degradation has increased the duration of action but not the potency. Previous results with a protected pentapeptide, [N-methyl-TyrlIenkephalinamide, are consistent with this observation (Bradbury et al., 1977) . However, while [D-Ala2lenkephalinamide has an increased duration of action relative to the transient effects of enkephalin, it also appears to be a little more potent without having a significantly increased binding affinity for the opiate receptors (Pert et al., 1976) . This could indicate that factors in addition to affinity for a receptor may influence potency. It is possible, for example, that the agonists may vary in their transport properties (ability to penetrate the receptor) or having bound may possess different intrinsic efficacies. The D-alanine2-and N-amide modifications woutd appear to enhance the potency of enkephalin, albeit mildly, by affecting one of these parameters. It is also of interest that although the D-alanine2-modified peptide is relatively resistant to enzymic degradation and has a longer lasting analgesic action than enkephalin, its effects are less persistent than those off,-endorphin (Fig. 6 ). Other stabilized peptides have been reported (Walker et al., 1977) , but their properties have not been compared with those of the longer peptides.
The present results show that the potent analgesic activity off,-endorphin is severely impaired by loss of the four C-terminal residues or by acetylation at the N-terminus (Table 1) . Since the peptides formed 
